Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
Recruiting · NCT07776054 · Interventional (participants receive a specific treatment) · Lead sponsor: Samsung Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
What this trial is about
SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≥19 years
- Persistent atrial fibrillation
- H2FPEF score ≥6 or HFA-PEFF score ≥5
- Restoration of sinus rhythm after electrical cardioversion
Exclusion criteria
- Previous use of an SGLT2 inhibitor
- Intracardiac thrombus on transesophageal echocardiography
- Refusal to participate
Where it is running
2 locations listed.
- Samsung Medical Center - Seoul, Seoul, South Korea
- Samsung Medical Center - Seoul, Seoul, South Korea